Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018

Publisher Name :
Date: 09-Oct-2018
No. of pages: 54
Inquire Before Buying

Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypertrophic Cardiomyopathy - Overview
Hypertrophic Cardiomyopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hypertrophic Cardiomyopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development
C&C BioPharma LLC
Lead Discovery Center GmbH
MyoKardia Inc
Hypertrophic Cardiomyopathy - Drug Profiles
8-MI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LUS-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mavacamten - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Agonize MFN2 for Charcot Marie Tooth Disease Type IIA and Hypertrophic Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cardiac Hypertrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GRK5 for Type 2 Diabetes and Cardiac Hypertrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block TRPC6 for Diabetic Nephropathy, Hypertrophy Cardiomyopathy and Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypertrophic Cardiomyopathy - Dormant Projects
Hypertrophic Cardiomyopathy - Product Development Milestones
Featured News & Press Releases
Jun 26, 2018: MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
May 21, 2018: MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
May 10, 2018: MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Apr 02, 2018: MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients
Mar 08, 2018: MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
Nov 15, 2017: Preclinical Studies with MyoKardias Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance
Nov 13, 2017: MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
Nov 02, 2017: MyoKardia Provides Update on Mavacamten
Nov 01, 2017: MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions
Sep 18, 2017: MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America's 21st Annual Scientific Meeting
Aug 07, 2017: MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Nov 11, 2016: MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
Nov 02, 2016: MyoKardia Announces Dosing of First Patient in Phase 2 PIONEER-HCM Study of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Sep 21, 2016: MyoKardia Outlines Path to Registration for MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients and Provides Pipeline and Research Updates at Inaugural R&D Day
Jul 14, 2016: SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Hypertrophic Cardiomyopathy - Pipeline by C&C BioPharma LLC, H2 2018
Hypertrophic Cardiomyopathy - Pipeline by Lead Discovery Center GmbH, H2 2018
Hypertrophic Cardiomyopathy - Pipeline by MyoKardia Inc, H2 2018
Hypertrophic Cardiomyopathy - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Myocardial Infarction Drugs Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 118
    In 2017, the global Myocardial Infarction Drugs market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Myocardial Infarction Drugs market based on company, product type, application and key regions. This report studies the global market size of Myocardial Infarction Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Mi......
  • Global and Chinese Myocardial Infarction Drugs Industry, 2018 Market Research Report
    Published: 10-Dec-2018        Price: US 3000 Onwards        Pages: 136
    The 'Global and Chinese Myocardial Infarction Drugs Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Myocardial Infarction Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Myocardial Infarction Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview......
  • Global and Chinese Rosuvastatin Industry, 2018 Market Research Report
    Published: 10-Dec-2018        Price: US 3000 Onwards        Pages: 150
    The 'Global and Chinese Rosuvastatin Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Rosuvastatin industry with a focus on the Chinese market. The report provides key statistics on the market status of the Rosuvastatin manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, ap......
  • Global and Chinese Rosuvastatin Calcium Industry, 2018 Market Research Report
    Published: 09-Dec-2018        Price: US 3000 Onwards        Pages: 139
    The 'Global and Chinese Rosuvastatin Calcium Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Rosuvastatin Calcium industry with a focus on the Chinese market. The report provides key statistics on the market status of the Rosuvastatin Calcium manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry incl......
  • Global and Chinese Atorvastatin Calcium Industry, 2018 Market Research Report
    Published: 09-Dec-2018        Price: US 3000 Onwards        Pages: 149
    The 'Global and Chinese Atorvastatin Calcium Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Atorvastatin Calcium industry with a focus on the Chinese market. The report provides key statistics on the market status of the Atorvastatin Calcium manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry incl......
  • Global Myocardial Ischemia Drugs Market Insights, Forecast to 2025
    Published: 04-Dec-2018        Price: US 3900 Onwards        Pages: 117
    In 2017, the global Myocardial Ischemia Drugs market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Myocardial Ischemia Drugs market based on company, product type, application and key regions. This report studies the global market size of Myocardial Ischemia Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle E......
  • Investigation Report on China’s Rosuvastatin Market, 2018-2022
    Published: 29-Nov-2018        Price: US 2200 Onwards        Pages: 30
    Rosuvastatin was first developed by Japanese company Shionogi & Co., Ltd. in the late 1980s. In Jun. 1998, Shionogi & Co., Ltd. transferred the right to develop, market and sell Rosuvastatin worldwide to AstraZeneca. The development code of Rosuvastatin by AstraZeneca is ZD-4522. Rosuvastatin was first approved in the Netherlands on Nov. 7, 2002, approved by the Health Council of Canada in Feb. 2003, and by the FDA on Aug. 12, 2003. The trade name of Astra......
  • Global Heart Failure Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 29-Nov-2018        Price: US 3480 Onwards        Pages: 135
    The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast pe......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Heart Failure Drugs Market 2018, Forecast to 2023
    Published: 29-Nov-2018        Price: US 4880 Onwards        Pages: 137
    The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast pe......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs